Clinical Trial Update: Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ORM-12741 for agitation/aggression in Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ORM-12741

Snippet

Sponsor: Orion Corporation, Orion Pharma | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED